List of Excipients in Branded Drug ILLUCCIX

Illuccix Excipient Strategy and Commercial Opportunities in PSMA PET Imaging

Last updated: August 29, 2026

Illuccix is a kit for preparing gallium Ga 68 gozetotide injection, a PSMA-targeted PET imaging agent marketed by Telix Pharmaceuticals. Its commercial value depends less on the excipient cost than on formulation reliability, radiolabeling yield, generator compatibility, shelf life, sterile handling, and radiopharmacy workflow. The strongest opportunities are excipient systems that improve radiochemical stability and manufacturing reproducibility without increasing kit complexity or creating avoidable regulatory hurdles.

What is Illuccix and how does its formulation work?

Illuccix is supplied as a kit for radiolabeling gozetotide with gallium-68. The resulting product is administered intravenously for PET imaging of PSMA-positive lesions in prostate cancer. The kit is used with gallium-68 obtained from an approved generator or another authorized source, followed by preparation under radiopharmacy conditions (U.S. Food and Drug Administration [FDA], 2022a).

The formulation strategy has four technical objectives:

1. Maintain gozetotide stability before radiolabeling.
2. Produce high radiochemical yield after addition of gallium-68.
3. Limit radiolysis during the short period between preparation and administration.
4. Preserve sterility, acceptable pH, and injectable tolerability.

Illuccix is therefore a process-dependent drug product. Its excipient system must perform during radiolabeling, not merely during storage of a conventional liquid injection.

What excipients are relevant to Illuccix?

Public FDA labeling identifies the kit as containing gozetotide and a reaction buffer used to prepare gallium Ga 68 gozetotide injection. The formulation is based on a controlled aqueous buffering environment rather than a complex delivery system. Sodium acetate is central to the radiolabeling environment, while other formulation components support peptide stability, isotonicity, pH control, and protection from degradation (FDA, 2022a).

The commercially relevant excipient functions are:

Excipient function	Strategic purpose in Illuccix
Acetate buffering	Maintains a pH range suitable for gallium chelation and peptide stability
Tonicity control	Supports intravenous tolerability
Antioxidant or radical-scavenging protection	Limits radiolysis and oxidative degradation
Chelation-compatible formulation	Avoids excipients that bind gallium or interfere with labeling
Low-bioburden sterile vehicle	Supports aseptic radiopharmacy preparation
Container-closure protection	Limits adsorption, leachables, and exposure-related degradation

The critical design constraint is compatibility. A conventional antioxidant, preservative, chelator, surfactant, or metal impurity can reduce labeling performance or affect radiochemical purity. Excipients must be evaluated for their effect on gallium speciation, peptide binding, radiolysis, sterility, and post-labeling stability.

What excipient strategy best supports Illuccix manufacturing?

The preferred strategy is a minimal, acetate-buffered, single-use kit with tightly controlled raw materials and validated radiolabeling conditions.

Buffer selection and pH control

Acetate buffer is commercially attractive because it supports gallium chelation while remaining familiar to radiopharmacy manufacturers. The buffer must be strong enough to control pH after addition of generator eluate but not so concentrated that it impairs labeling or increases injection burden.

A formulation developer should optimize:

• Buffer concentration.
• Starting pH.
• Final pH after gallium-68 addition.
• Generator eluate volume.
• Elution acidity and residual metal content.
• Reaction temperature.
• Reaction time.
• Final dilution volume.

The key commercial claim is not simply “acetate buffer.” A stronger development position would link a defined buffer range to radiochemical yield, radiochemical purity, stability, or compatibility with a specified class of gallium-68 generators.

Radiolysis control

Gallium-68 emits high-energy radiation during preparation and administration. Radiolysis can generate oxidized peptide species, breakdown products, and reduced radiochemical purity. Antioxidant protection may improve the usable time between labeling and injection.

Potential approaches include:

• Gentisic acid or related radical scavengers.
• Ascorbate-based protection.
• Methionine or other sacrificial amino acids.
• Controlled dissolved oxygen.
• Low peptide concentration with optimized reaction chemistry.
• Light-protective packaging.
• Reduced hold time before administration.

Any antioxidant must be tested for gallium binding, pH impact, injection tolerability, and interference with analytical release testing. The best commercial formulation may use an established antioxidant at a narrow concentration range rather than introducing a novel excipient.

Peptide concentration and adsorption

Low-dose radiopharmaceutical peptides can adsorb to glass, elastomeric closures, tubing, filters, and automated synthesis components. This creates a risk of dose loss and batch-to-batch variability.

Commercial formulation work should measure:

• Recovery from the reaction vial.
• Recovery through transfer tubing.
• Recovery after filtration.
• Binding to syringe and needle materials.
• Stability in the final dose container.
• Effect of surface treatment or low-binding polymer components.

A formulation that reduces adsorption without adding a surfactant could be more attractive than one that relies on a new excipient. Surfactants may introduce additional toxicity, extractables, and regulatory review.

What formulations are protected by Illuccix-related intellectual property?

The principal protectable value is likely to reside in the overall preparation process and kit configuration rather than in a widely used buffer alone. Excipient-related patent claims could cover:

• Defined gozetotide-to-gallium molar ratios.
• Acetate-buffer concentration and pH windows.
• Antioxidant combinations that maintain radiochemical purity.
• Generator eluate conditioning.
• Reaction temperature and labeling time.
• Sterile filtration and dose dispensing.
• Container-closure systems.
• Stability of the radiolabeled product over a defined post-labeling period.
• Automated or semi-automated kit preparation.
• Compatibility with specific gallium-68 generator formats.

A patent claiming only “gozetotide in acetate buffer” would face prior-art pressure because peptide radiolabeling buffers and gallium chelation systems are well established. Stronger claims would show an unexpected result, such as materially improved radiochemical purity, longer usable shelf life, higher yield across multiple generator eluate profiles, or reduced radiolysis.

How strong is the excipient patent estate for Illuccix?

The formulation estate should be viewed as moderate rather than structurally dominant. The active ligand, PSMA targeting concept, gallium-68 labeling chemistry, kit architecture, and preparation process may provide more meaningful protection than the excipients themselves.

Key strength factors are:

Factor	Assessment
Novelty of common buffers	Limited
Novelty of specific concentration ranges	Potentially meaningful
Radiolysis-control claims	Potentially strong if supported by comparative data
Generator compatibility claims	Commercially relevant
Kit and workflow claims	Important for differentiation
Manufacturing know-how	Likely valuable even where patent scope is narrow
Regulatory exclusivity	Limited compared with conventional small-molecule drugs

Public FDA materials do not establish that a single excipient patent controls all commercial versions of gallium Ga 68 gozetotide. Patent expiration dates and Orange Book-listed claims should be confirmed against current USPTO and FDA records before a freedom-to-operate decision.

How does Illuccix compare with Locametz and Pylarify?

Illuccix competes most directly with Locametz, another gallium Ga 68 gozetotide kit. Pylarify uses a different PSMA-targeting radioligand labeled with fluorine-18 and is supplied as a finished injection rather than a gallium-68 preparation kit (FDA, 2021; FDA, 2022b).

Product	Radioligand	Radionuclide	Dosage form	Excipient and workflow implication
Illuccix	Gozetotide	Ga-68	Kit for preparation	Depends on generator eluate and local radiopharmacy labeling
Locametz	Gozetotide	Ga-68	Kit for preparation	Similar chelation, buffer, sterility, and generator issues
Pylarify	Piflufolastat	F-18	Ready-to-use injection	Greater reliance on centralized production and distribution
Axumin	Fluciclovine F-18	F-18	Ready-to-use injection	Finished-dose logistics and fluorine-18 supply chain

Illuccix and Locametz have similar technical exposure to acetate buffering, generator variability, radiolysis, and short post-labeling use periods. Their commercial differentiation can come from:

• Kit simplicity.
• Reaction time.
• Yield across generator types.
• Dose recovery.
• Stability after labeling.
• Automated preparation.
• Radiopharmacy training requirements.
• Distribution and reimbursement support.

Pylarify has a different commercial profile. Its ready-to-use format reduces local labeling complexity but requires access to an F-18 production and distribution network. Illuccix can be more attractive for sites with established gallium-68 generators and radiopharmacy infrastructure.

What commercial opportunities exist for Illuccix excipient innovation?

The highest-value opportunities are workflow improvements that reduce failed preparations and expand use beyond high-volume academic centers.

Generator-compatible formulation systems

Gallium-68 generators differ in eluate volume, acidity, breakthrough profile, and trace-metal burden. A formulation that maintains yield across multiple generator platforms could support broader hospital adoption.

A commercially valuable product could include:

• A standardized buffer vial.
• Generator-specific preparation instructions.
• Validated release specifications.
• Automated synthesis compatibility.
• A documented adjustment for eluate volume or acidity.

This opportunity is more defensible when supported by comparative data across generator manufacturers.

Longer post-labeling stability

A longer usable period after labeling can improve scheduling and reduce dose wastage. A formulation that maintains radiochemical purity for additional hours could support:

• Multiple patient doses from one preparation.
• More flexible imaging schedules.
• Lower failed-dose rates.
• Improved radiopharmacy labor utilization.
• Broader regional distribution.

The opportunity is constrained by gallium-68’s physical half-life of about 68 minutes. Chemical stability cannot overcome radioactive decay, but it can improve operational flexibility during the available dosing window.

Automated radiopharmacy preparation

Excipient selection should be compatible with automated modules, sterile cassettes, and closed-system transfer devices. This creates opportunities for:

• Premeasured buffer components.
• Reduced manual transfers.
• Lower operator radiation exposure.
• Fewer preparation errors.
• Digital batch records.
• Integrated quality-control testing.

A kit designed for automation could command a premium if it lowers labor and compliance costs.

Radiolysis-resistant packaging

Low-binding vials, optimized elastomeric closures, light protection, and reduced oxygen exposure can support product consistency. Packaging claims may be commercially useful when they solve dose recovery or stability problems without requiring a new excipient.

Contract development and manufacturing

Specialized radiopharmaceutical CDMOs can offer:

• Kit filling.
• Sterile lyophilization.
• Generator compatibility studies.
• Radiolabeling validation.
• Automated synthesis integration.
• Stability and extractables testing.
• Regional release testing.

The opportunity is strongest in markets where hospitals lack internal radiopharmaceutical development capabilities.

What FDA regulatory status and exclusivity apply to Illuccix?

The FDA approved Illuccix in September 2022 for preparation of gallium Ga 68 gozetotide injection for PET imaging of PSMA-positive lesions in patients with prostate cancer (FDA, 2022a). It is regulated as a radiopharmaceutical kit rather than as a conventional oral small-molecule product.

When does Illuccix lose exclusivity?

Illuccix does not have the same commercial exclusivity profile as a conventional new chemical entity. Its commercial protection depends on the combination of:

• Patent rights.
• Product-specific formulation and manufacturing know-how.
• Regulatory status.
• Radiopharmacy distribution.
• Generator and production capacity.
• Institutional contracts.
• Reimbursement and clinical adoption.

The FDA approval date alone does not provide a reliable patent-expiration date. Any launch analysis should separate statutory regulatory exclusivity from patent protection and from practical supply-chain barriers.

What is the Orange Book status of Illuccix?

The Orange Book is less informative for a radiopharmaceutical kit than for a conventional prescription drug with listed composition, method-of-use, and formulation patents. Orange Book listing status should be checked in the current FDA publication and matched against issued patents and pending applications. Absence of a prominent Orange Book listing would not eliminate infringement risk from process, kit, manufacturing, or non-Orange-Book patent claims (FDA, 2025).

What generic entry risks exist for Illuccix?

Generic or competing entry is technically possible but operationally more difficult than copying a conventional sterile injection. An entrant must reproduce or replace:

• The gozetotide peptide and chelation performance.
• The kit’s radiolabeling process.
• Sterility and endotoxin controls.
• Generator compatibility.
• Radiochemical release testing.
• Short-window distribution.
• Radiopharmacy operating procedures.

The principal entry scenarios are:

Entry scenario	Commercial risk
Competing Ga-68 gozetotide kit	Highest direct substitution risk
Alternative Ga-68 PSMA ligand	Moderate clinical and regulatory substitution risk
F-18 PSMA product	Moderate to high, depending on imaging capacity
Hospital-compounded preparation	Limited by regulatory and quality requirements
Regional radiopharmacy service	Could reduce kit demand in selected markets
Improved automated kit	Could capture premium sites and high-volume centers

Paragraph IV litigation is less predictable than in high-volume oral drugs because the relevant patents may cover radiolabeling processes, kits, manufacturing methods, or use claims rather than a single clearly listed Orange Book patent. Publicly confirmed litigation, settlement, and launch dates should be verified from court dockets and FDA records before relying on them in a transaction model.

How should a company build an Illuccix excipient IP strategy?

A practical strategy has three layers.

Patent claims

Focus claims on measurable performance:

• Radiochemical purity after a specified hold time.
• Yield across defined generator eluate conditions.
• Stability under defined activity concentrations.
• Reduced adsorption during automated transfer.
• Defined antioxidant-to-peptide ratios.
• Kit architecture and sequential addition steps.

Trade secrets

Protect information that may be difficult to detect in a finished dose:

• Raw-material specifications.
• Trace-metal limits.
• Generator conditioning.
• Mixing order.
• Reaction timing.
• Sterile filtration parameters.
• Cleaning and changeover procedures.
• Analytical acceptance criteria.

Regulatory differentiation

Create a dossier showing:

• Consistent radiochemical yield.
• Reproducibility across lots and generators.
• Low radiolysis.
• Sterility assurance.
• Container-closure integrity.
• Compatibility with automated systems.
• Practical post-labeling stability.

This evidence can support licensing, hospital conversion, CDMO partnerships, and premium pricing even where patent scope is limited.

Key Takeaways

• Illuccix is a gallium-68 gozetotide radiolabeling kit, not a conventional finished-dose injection.
• Its excipient strategy centers on acetate buffering, radiolysis control, tonicity, sterility, and generator compatibility.
• Common excipients alone provide limited patent protection.
• Stronger IP claims should connect defined excipient ranges to radiochemical yield, stability, dose recovery, or automated preparation.
• The largest commercial opportunities are longer post-labeling stability, generator compatibility, reduced dose wastage, and automation.
• Locametz is the closest direct competitor because it uses the same gozetotide and gallium-68 platform.
• Pylarify competes through a finished fluorine-18 product with a different manufacturing and distribution model.
• Generic entry is constrained by short radioactive half-life, radiopharmacy infrastructure, sterile manufacturing, and analytical release requirements.
• Patent, Orange Book, Paragraph IV, and settlement conclusions require current record-level verification.

FAQs About Illuccix Excipients and Commercial Strategy

Does Illuccix contain a preservative?

Illuccix is a sterile radiopharmaceutical kit and is not positioned as a multidose product preserved through conventional antimicrobial preservatives. Its formulation relies on aseptic manufacture, sterile handling, and controlled preparation.

Can the Illuccix formulation be converted into a ready-to-use injection?

A ready-to-use presentation would require validated post-labeling stability, sterile storage, radiochemical release controls, and a distribution model compatible with gallium-68 decay. The physical half-life makes centralized ready-to-use distribution more difficult than local preparation.

What is the most valuable excipient improvement for Illuccix?

The most valuable improvement would likely be a formulation that maintains high radiochemical purity across variable generator eluates while extending the practical post-labeling use period.

Can antioxidants create new patent opportunities for gallium-68 PSMA products?

Yes, but a broad antioxidant claim would face prior-art challenges. Patent value is stronger when the antioxidant concentration, buffer system, radiolabeling conditions, and measurable stability benefit are claimed together.

Which commercial partner is most relevant for Illuccix formulation development?

Relevant partners include radiopharmaceutical CDMOs, sterile injectables manufacturers, automated radiopharmacy suppliers, gallium-68 generator manufacturers, and regional nuclear pharmacies. The best partner depends on whether the objective is kit manufacturing, automation, generator compatibility, or regional distribution.

References

1. U.S. Food and Drug Administration. (2021). PYLARIFY (piflufolastat F 18) injection prescribing information.
2. U.S. Food and Drug Administration. (2022a). ILLUCCIX (kit for the preparation of gallium Ga 68 gozetotide injection) prescribing information.
3. U.S. Food and Drug Administration. (2022b). LOCAMETZ (kit for the preparation of gallium Ga 68 gozetotide injection) prescribing information.
4. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations.
5. Telix Pharmaceuticals Limited. (2024). Annual report and corporate disclosures.